Tag Archives: Row over remdesivir’s efficacy as Covid-19 drug

ZURICH: A row broke out on Friday over a World Health Organisation (WHO) clinical trial which concluded that the anti-viral drug remdesivir has little or no impact on a patient’s chances of surviving Covid-19. Gilead Sciences Inc., the US company that developed the drug, said the findings appeared inconsistent with evidence from other studies validating the clinical benefit of remdesivir, …

Read More »